Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered t cells target deadly brain cancers in new trial

NCT ID NCT04099797

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 37 times

Summary

This study tests a new treatment for people with brain tumors that have a protein called GD2. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack the tumor. A special gene is added to help these cells survive longer in the body. The study aims to find the safest dose and see if the cells can shrink the tumor. About 56 participants with specific brain cancers will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Texas Children's Hospital

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.